Results 151 to 160 of about 14,668 (165)
Daratumumab for the Treatment of Multiple Myeloma [PDF]
This mini-review will summarize the present state of development of the CD38 antibody daratumumab for the treatment of multiple ...
Torben Plesner, Jakub Krejcik
exaly +2 more sources
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma [PDF]
BACKGROUND Daratumumab, a human IgG kappa monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy in heavily pretreated patients with multiple myeloma, as well as in ...
Tomer M Mark +2 more
exaly +2 more sources
Daratumumab is a fully human anti-CD38 IgG1-κ monoclonal antibody (mAb) currently being evaluated in several Phase 2 and 3 clinical studies for the treatment of multiple myeloma (MM).
Hans Jacobs +2 more
exaly +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Targeting CD38 With Daratumumab in Refractory Systemic Lupus Erythematosus
New England Journal of Medicine, 2020Andreas Radbruch +2 more
exaly
Daratumumab for Delayed Red-Cell Engraftment After Allogeneic Transplantation
New England Journal of Medicine, 2018Jean M Connors +2 more
exaly
Daratumumab Plus Lenalidomide and Dexamethasone for Untreated Myeloma
New England Journal of Medicine, 2019Shaji K Kumar +2 more
exaly
F(Ab′)2 Fragments to Overcome Daratumumab Interference in Transfusion Tests
New England Journal of Medicine, 2018Thomas Thiele, Kathleen Selleng
exaly
Targeting CD38 With Daratumumab Monotherapy in Multiple Myeloma
New England Journal of Medicine, 2015Jacob P Laubach +2 more
exaly

